Results 201 to 210 of about 693,900 (279)

PARP inhibitors in gastric cancer: unlocking precision oncology. [PDF]

Oncologist
Tai D, Goes V, Kumar S, Shah P, Al-Manaseer F, Park D, Crook C, Guzman S, Zhu X, Li D, Castillo D.   +10 more
europepmc   +1 more source

Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer. [PDF]

Proc Natl Acad Sci U S A
Traphagen NA, Wheeler E, Li R, Akhshi T, Ravindranathan R, Alfieri C, Lu F, Ahmed B, Tewari AK, Balk SP, Nelson PS, Corey E, Long H, D'Andrea AD, Qiu X, Brown M.   +15 more
europepmc   +1 more source

Dysglycaemia and Autonomic Dysfunction: The Diabetes Prevention Program Outcomes Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Limited data on the link between various measures of glycemia and metabolism and autonomic dysfunction exist. We assessed the association of fasting plasma glucose [FPG], glycated haemoglobin [HbA1C], fasting insulin, and HOMA‐IR and cardiac autonomic function measures separately for men and women in the Diabetes Prevention Program ...
Justin B. Echouffo‐Tcheugui, Xun Liu, Elsayed Z. Soliman, Xavier Pi‐Sunyer, Sherita H. Golden, Sam Dagogo‐Jack, Neil H. White, Matthew Budoff, Uzoma Ibebuogu, Christine Darwin, William C. Knowler, Marinella Temprosa, on behalf of the DPP Research Group   +12 more
wiley   +1 more source

PARP inhibitors as radiosensitizers: a comprehensive review of preclinical evidence and clinical applications. [PDF]

Front Oncol
Luo X, Gao S, Sun K, Dong Z, Yang S.
europepmc   +1 more source

Human APOBEC3G suppresses homologous recombination and LIG4‐independent end joining in DNA double‐strand break repair

The FEBS Journal, EarlyView.
Chromosomal DNA double‐strand breaks (DSBs) are repaired by homologous recombination and nonhomologous end joining (NHEJ). Recent work has additionally established theta‐mediated end‐joining (TMEJ) as a mechanism for DSB joining. Cells lacking NHEJ and TMEJ can repair DSBs in a homology‐dependent manner.
Shinta Saito, Miori Murayama, Usaki Arai, Sekifumi Akatsu, Ami Yamamoto, Misaki Kadoguchi, Noritaka Adachi   +6 more
wiley   +1 more source

Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation. [PDF]

Clin Pharmacokinet
Torrent-Rodríguez A, Bastida C, Martín ECS, Escartín IM, Puszkiel A, Blanchet B, Laguna JC, Gorria T, Montes A, Macías I, Alvárez A, Arance A, Moreno FA, Fabregat-Bolufer AB, Soler E, Muner DS.   +15 more
europepmc   +1 more source

Tankyrase‐2 regulates adipocyte differentiation through AMPK/mTOR signaling

The FEBS Journal, EarlyView.
Tankyrase 2 (TNKS2), a PARP family member, underpins adipocyte differentiation. TNKS2 controls LKB1 protein level, and consequently, the activity of the mTOR/AMPK system and adipocyte differentiation through a layered process. Pharmacological inhibition of TNKS2 leaves other PARPs and DNA repair active and therefore represents a novel target in ...
Boglarka Rauch, Gyula Ujlaki, Szilard Poliska, Nakayi Murahwa, Patrik Kovacs, Aladar Pettko‐Szandtner, Karen Uray, Peter Bai   +7 more
wiley   +1 more source

Cumulative cytotoxic chemotherapy exposure after the introduction of PARP inhibitors in advanced high-grade serous tubo-ovarian and primary peritoneal carcinoma: A descriptive single-center historical cohort study. [PDF]

Mol Clin Oncol
Osawa N, Chikazawa K, Imai K, Shimizu A, Ko H, Kuwata T.   +5 more
europepmc   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

The effect of photodynamic therapy in head and neck cancer: A comprehensive review of in vivo models

Photochemistry and Photobiology, EarlyView.
This review evaluates Photodynamic Therapy (PDT) in in vivo head and neck cancer models. PDT effectively generates ROS, reducing tumor growth, cell proliferation and angiogenesis while enhancing survival and immune responses. However, methodological heterogeneity highlights the urgent need for standardized dosimetric protocols to ensure reproducibility
Bibiana Padilha de Menezes da Silva, Rebeca Barros Nascimento, Giovanna Lopes Carvalho, Rebeca Boltes Cecatto, Maria Stella Moreira, Maria Fernanda Setúbal Destro Rodrigues   +5 more
wiley   +1 more source